<DOC>
	<DOC>NCT01734018</DOC>
	<brief_summary>This multicenter, prospective, observational study will evaluate the efficacy and safety of Pegasys (peginterferon alfa-2a) in routine clinical practice in patients with HBeAg-positive or HBeAg-negative chronic hepatitis B. Eligible patients receiving treatment with Pegasys according to standard of care and the summary od product characteristics/local labelling will be followed for the duration of treatment and up to 2 years of follow-up.</brief_summary>
	<brief_title>An Observational Study of Pegasys (Peginterferon Alfa-2a) in Patients With HBeAg-Positive or HBeAg-Negative Chronic Hepatitis B</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B, Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Adult patients, &gt;/= 18 years of age HBeAgpositive or HBeAgnegative serologically proven chronic hepatitis B with or without cirrhosis Elevated serum ALT &gt; ULN (upper limit of normal) but &lt;/=10 x ULN according to local label Contraindications to Pegasys as detailed in the label Coinfection with hepatitis A, hepatitis B or HIV Concomitant therapy with telbivudine (concomitant peginterferon alfa2a therapy is contraindicated according to telbivudine label) Pregnant or breastfeeding women</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>